Molecular profiling of bladder cancer xenografts defines relevant molecular subtypes and provides a resource for biomarker discovery.
Bladder cancer (BLCA) genomic profiling has identified molecular subtypes with distinct clinical characteristics and variable sensitivities to frontline therapy. BLCAs can be categorized into luminal or basal subtypes based on their gene expression. We comprehensively characterized nine human BLCA c...
Saved in:
Main Authors: | Sharada Mokkapati, Ganiraju Manyam, Alexis R. Steinmetz, Côme Tholomier, Alberto Martini, Woonyoung Choi, Bogdon Czerniak, Byron H Lee, Colin P Dinney, David J McConkey |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | Translational Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523324003954 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinicopathological study and molecular subtyping of muscle-invasive bladder cancer (MIBC) using dual immunohistochemical (IHC) markers
by: R. Vaithegi, et al.
Published: (2025-01-01) -
Immunohistochemistry‐based molecular subtypes of urothelial carcinoma derive different survival benefit from platinum chemotherapy
by: Csilla Olah, et al.
Published: (2025-01-01) -
A novel bladder cancer surveillance schedule using bladder Cx for patients on annual surveillance
by: Arjun Guduguntla, et al.
Published: (2025-01-01) -
Neoantigen immunotherapy: a novel treatment for bladder cancer
by: Ruiyang Lv, et al.
Published: (2025-01-01) -
A model of thermotherapy treatment for bladder cancer
by: Christoph Sadée, et al.
Published: (2016-07-01)